Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1178670 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $242.61 · Day +6.12% · Mkt cap $30.6B · P/E (FY) 98.1× · 1Y −47.1% · Off 52W high −51.0% · Vol (1Y) 46.0% Price2023-08-21 → 2026-08-19 ALNY close: $189 on 2023-08-21 to $243 on 2026-08-19. Split-adj closes · 240 of 5,309 · price returnⓘ At a glance | Short interest3.6% of sh out | | Days to cover2.2d | | 13F net flow (QoQ)+1.99% | | Top-10 13F concentration58.5% | | Next report (est.)2026-10-29 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)98.1× | | Sales (TTM)$3.71B | | Earnings (TTM)$774.7M | | ROE73.3% | | Net margin8.4% | | Sales growth 3Y53.0% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−39.0% | | 1Y−47.1% | | 3Y+28.5% | | 5Y+23.2% | | 10Y+233.3% | | Since incept. (ann.)+18.2% |
Total return · from 2005-07-08ⓘ Risk | Ann. volatility (1Y)46.0% | | Ann. volatility (3Y)46.9% | | Sharpe (1Y)−1.14 | | Sharpe (3Y)0.42 | | Max drawdown (1Y)−58.2% | | Max drawdown (3Y)−58.2% | | Beta (3Y vs SPY)1.05 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| FMR LLC | 14.6M | $4.8B | 10.99% | −8.3% | | Capital World Investors | 10.8M | $3.6B | 8.15% | −33.7% | | BlackRock, Inc. | 10.4M | $3.5B | 7.88% | +0.4% | | Capital Research Global Investors | 9.5M | $3.1B | 7.14% | +39.7% | | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.5M | $2.1B | 4.89% | new | | JPMORGAN CHASE & CO | 6.3M | $2.0B | 4.77% | +34.0% | | VANGUARD CAPITAL MANAGEMENT LLC | 5.9M | $2.0B | 4.48% | new | | T. Rowe Price Investment Management, Inc. | 5.2M | $1.7B | 3.92% | +78.8% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-07-30 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-07-30 | $1.21 | — | $1.29B | +66.9% | | 2025-12-31 | 2026-02-12 | — | — | $1.10B | +84.9% | | 2025-09-30 | 2025-10-30 | $1.84 | — | $1.25B | +149.3% | | 2025-06-30 | 2025-07-31 | −$0.55 | — | $773.7M | +17.3% |
As-reported XBRL · next 2026-10-29 est.ⓘ Segment mixFY2025 (ended Dec 2025) Product 31% · TTR 26% · Amvuttra 24% · Collaborations 6% · Rare 5% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
